Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behçet's Disease

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 808-811

  Sayarlioglu, Mehmet ^a   Kotan, Mehmet Cetin ^a   Topcu, Nazan ^a   Bayram, Irfan ^a   Arslanturk, Hasan ^a   Gul, Ahmet ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Thalidomide

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ARTICLE; BEHCET DISEASE; CASE REPORT; CECUM; CELL MIGRATION; CLINICAL FEATURE; COLON; CYTOKINE PRODUCTION; EMERGENCY TREATMENT; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; ILEUM; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ULCER; LAPAROTOMY; NEUTROPHIL; PRIORITY JOURNAL; RECURRENT DISEASE; ULCER PERFORATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; BEHCET SYNDROME; FEMALE; HUMANS; INTESTINAL PERFORATION; RECURRENCE; THALIDOMIDE;

EID: 1942534722     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D524     Document Type: Article

References (23)

1. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
2. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(5 suppl 24):S6-12.
3. Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behçet disease (Behçet syndrome). Semin Arthritis Rheum 1979;8:223-60.
4. Yurdakul S, Tüzüner N, Yurdakul I, Hamuryudan V, Yazici H. Gastrointestinal involvement in Behçet's syndrome: a controlled study. Ann Rheum Dis 1996;55:208-10.
5. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease - an update. Semin Arthritis Rheum 2001;30:299-312.
6. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962;267:1184-92.
7. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984;11:814-9.
8. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome (letter). Arch Dermatol 1982;118:536.
9. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol 1986;5:365-71.
10. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
11. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
12. Postema PT, den Haan P, van Hagen PM, van Blankenstein M. Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996;8:929-31.
13. Terrin G, Borrelli O, Di Nardo G, Pacchiarotti C, Cucchiara S. A child with aphthae and diarrhoea. Lancet 2002;359:316.
14. Larsson H. Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). J Intern Med 1990;228:405-7.
15. Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and non-surgical patients with intestinal Behçet's disease. Am J Gastroenterol 2000;95:2848-51.
16. Lee KS, Kim SJ, Lee BC, Yoon DS, Lee WJ, Chi HS. Surgical treatment of intestinal Behçet's disease. Yonsei Med J 1997;38:455-60.
17. Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum 2000;43:692-700.
18. Shek LP, Lim DL. Thalidomide in Behçet's disease. Biomed Pharmacother 2002;56:31-5.
19. Sakane T. New perspective on Behçet's disease. Int Rev Immunol 1997; 14:89-96.
20. Ehrlich GE. Vasculitis in Behçet's disease. Int Rev Immunol 1997;14:81-8.
21. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
22. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
23. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79.